Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) had its price objective hoisted by research analysts at JPMorgan Chase & Co. from $167.00 to $168.00 in a report released on Thursday,Benzinga ...

Iterum Therapeutics plc (NASDAQ:ITRM), a pharmaceutical company with a market capitalization of $53.43 million, has reported a regulatory compliance issue with the Nasdaq Stock Market. According to ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...

Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its ...

Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

Following the earnings announcement, WST stock plummeted 38% due to its disappointing guidance. Over a broader timeframe, its ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a ...